Human prion proteins expressed in Escherichia coli and purified by high-affinity column refolding  by Zahn, Ralph et al.
FEBS Letters 417 (1997) 400-404 FEBS 19478 
Human prion proteins expressed in Escherichia coli and purified by 
high-affinity column refolding 
Ralph Zahn, Christine von Schroetter, Kurt Wuthrich* 
Institut fur Molekularhiologie und Biophysik, Eidgenossische Technische Hochschule Honggerherg, CH-8093 Zurich, Switzerland 
Received 17 October 1997 
Abstract An efficient method is presented for the production of 
intact mammalian prion proteins and partial sequences thereof. 
As an illustration we describe the production of polypeptides 
comprising residues 23-231, 81-231, 90-231 and 121-231 of the 
human prion protein (APrP)1. Polypeptides were expressed as 
histidine tail fusion proteins into inclusion bodies in the 
cytoplasm of Escherichia coli and refolded and oxidized while 
N-terminally immobilized on a nickel-NTA agarose resin. This 
'high-affinity column refolding' facilitates the preparation of 
prion proteins by preventing protein aggregation and intermo-
lecular disulfide formation. After elution from the resin the 
histidine tail can be removed using thrombin without cleaving the 
prion protein polypeptide chain. The same protocol as used here 
for APrP has been successfully applied with bovine and murine 
prion proteins. The protein preparations are stable for weeks at 
room temperature in concentrated solution and are thus suitable 
for detailed structural studies. Preliminary biophysical charac-
terization of APrP(23-231) suggests that the C-terminal half of 
the polypeptide chain forms a well-structured globular domain, 
and that the N-terminal half does not form extensive regular 
secondary structures. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Mammalian prion proteins (PrP) have a 22-amino acid N-
terminal signal sequence [2,3], and a 23-amino acid C-terminal 
signal sequence encoding attachment of a glycosylphosphati-
dylinositol (GPI) anchor [4,5]. The mature protein of 208 or 
209 amino acids contains one disulfide bond [3], and has two 
asparagine-linked glycosylation sites [6,7]. Keen interest is fo-
cused on PrP since evidence has been presented that post-
translational conversion of a ubiquitous cellular isoform 
(PrPc) into the scrapie isoform (PrPSc) is the fundamental 
process underlying transmission and pathogenesis of transmis-
sible spongiform encephalopathies (TSEs), which include 
kuru, Creutzfeldt-Jakob disease (CJD), Gerstmann-Strauss-
ler-Scheinker syndrome (GSS) and fatal familial insomnia 
(FFI) in humans, bovine spongiform encephalopathy (BSE), 
and scrapie in sheep (for recent reviews see, for example, [8-
10]). This 'protein-only' hypothesis [11,12] provides a ration-
ale for the observation that inherited TSEs can be transmitted 
to laboratory animals, which is a unique feature in currently 
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1 Sequence positions according to Syrian hamster PrP [1]. 
known genetic diseases [13] so that its further investigation is 
of general interest. TSE research will also in the future rely on 
the availability of high quality preparations of prion protein 
[10]. This paper describes an efficient procedure for the pro-
duction of recombinant prion proteins in Escherichia coli that 
is based on 'high-affinity column refolding'. 
Alternative procedures for the production of recombinant 
mammalian prion protein or fragments thereof have previ-
ously been reported. Syrian hamster PrP (shPrP) comprising 
residues 90-231, which corresponds to the protease-resistant 
PrP 27-30 form [13], was expressed as an insoluble protein in 
the cytoplasm of Escherichia coli [14]. Other shPrP constructs 
could not be expressed using the same expression system be-
cause of protein degradation. After solubilization in 8 M 
GdmCl .v/iPrP(90-231) was purified by size exclusion chroma-
tography and reversed phase chromatography. Purification 
under reducing conditions yielded a high content of P-sheet 
and relatively low solubility, similar to PrPSc, whereas refold-
ing by oxidation to form a disulfide bond between the two 
cysteinyl residues produced a soluble protein with a high a-
helix content, similar to PrP c . 
Recombinant mouse PrP comprising residues 121-231, 
mPrP(121-231), was expressed as a soluble protein in the 
periplasm of E. coli using an OmpA signal sequence [15]. 
Larger fragments of wPrP were amino-terminally degraded 
during periplasmic expression. mPrP(121-231) was purified 
by anion-exchange chromatography, hydrophobic chromatog-
raphy and gel filtration. HPLC analysis revealed that the sin-
gle disulfide bond was quantitatively present in the purified 
protein. The nuclear magnetic resonance (NMR) structure of 
mPrP(121-231) [16] shows a high content of a-helices and a 
small |3-sheet, which coincides with earlier characterization of 
the PrP c form of prion proteins by biophysical methods 
[17,18]. 
The intact mPrP polypeptide was expressed in inclusion 
bodies in the cytoplasm of E. coli [19], and was purified by 
conventional chromatographic techniques, including ion-ex-
change chromatography and reversed phase chromatography. 
Oxidation of the purified protein was performed in basic buff-
er containing 8 M urea and 1 (iM CuS04 . NMR experiments 
on mPrP(23-231) in aqueous solution at pH 4.5 showed that 
the previously determined globular three-dimensional struc-
ture of the C-terminal domain wPrP(121-231) is preserved 
in the intact protein, and that the N-terminal polypeptide 
segment 23-120 is flexibly disordered [20]. Intact bovine PrP 
has been expressed as a fusion protein with a histidine tag in 
E. coli [21], which was purified via a nickel-NTA column and 
refolded by dialysis from 8 M urea into buffer. 
The method described here for expression and purification 
of prion proteins is illustrated with the production of poly-
peptides comprising residues 23-231, 81-231, 90-231, and 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97)01330-6 
R. Zahn et al.lFEBS Letters 417 (1997) 400^04 401 
121-231 of human PrP (ZzPrP). The proteins were expressed as 
inclusion bodies in the cytoplasm of E. coli in a construct with 
an N-terminal histidine tail and an engineered thrombin cleav-
age site. The critical step for the production of APrP is its 
renaturation to the correctly folded protein [14,19,21]. Here, 
refolding of the histidine tail-fused PrPs immobilized to a 
nickel-NTA column prevented protein aggregation and fa-
vored intramolecular disulfide bond formation during refold-
ing. Using thrombin, the N-terminal histidine tail could be 
cleaved off without hydrolyzing the prion protein polypeptide 
chain. The purified APrP polypeptides were characterized by 
N M R , circular dichroism (CD), and fluorescence spectros-
copy. The same protocol has been successfully applied with 
PrP from different species (to be published elsewhere). 
2. Materials and methods 
2.1. Cloning of prion proteins 
The plasmid pRSET A (Invitrogen) for expression of mammalian 
prion proteins in E. coli encodes an N-terminal histidine tail that 
contains an engineered thrombin cleavage site [22]. The histidine tail 
is composed of 17 amino acids (MRGSHHHHHHGLVPRGS). The 
DNA of human prion protein ([23] accession number M13899) was 
obtained by polymerase chain reaction (PCR) of commercially avail-
able cDNA of human brain (Clontech). Two primers flanking the 
prion protein with BamHl and EcoKl restriction sites enabled us to 
clone the PCR fragment into the polylinker site of pRSET A. PCR 
was performed with Pfu (Stratagene) to reduce the risk of undesired 
random mutations. The reaction was performed in 25 ul volumes for 
25 cycles with 400 nM primer and 200 uM of each dNTP. The an-
nealing temperature was 60°C. The inserted DNA sequence was veri-
fied by the dideoxy-mediated chain-termination method. 
2.2. Expression and purification of prion proteins 
Freshly transformed overnight culture of E. coli BL21(DE3) cells 
(Stratagene) containing the respective plasmid for expression of prion 
protein was added at 37°C to 2 1 of Luria broth (LB) medium plus 
ampicillin (100 ug/ml). At OD60o = 0.5, expression was induced with 
isopropyl (3-D-galactopyranoside (IPTG) to a final concentration of 
1 mM. For isotope labeling a minimal medium (MM) containing 
1 g/1 [15N]ammonium chloride, 2 g/1 [13C6]glucose, and a vitamin cock-
tail (5 mg/1 thiamine, 1 mg/1 D-biotin, 1 mg/1 choline chloride, 1 mg/1 
folic acid, 1 mg/1 niacinamide, 1 mg/1 D-pantothenic acid, 1 mg/1 pyr-
idoxal hydrochloride, 0.1 mg/1 riboflavin) was used. Expression in 
MM was induced at an OD60o = 1-1. In each medium the cells were 
harvested 8 h after induction, centrifuged, resuspended in 100 ml 
buffer G (6 M GdmCl, 10 mM Tris-HCl, 100 mM Na2P04 , 10 mM 
reduced glutathione, pH 8.0), and further processed as outlined in Fig. 
1. After sonication and centrifugation, the soluble protein fraction 
was added to 30 ml of nickel-nitrilotriacetic acid (NTA) agarose resin 
(Qiagen) and stirred for 10 min. The resin was poured into a column 
and washed with 120 ml buffer G, and to the immobilized histidine 
tail-containing fusion protein we applied a 200 ml gradient of buffer 
G to buffer B (10 mM Tris-HCl, 100 mM Na2P04 , pH 8.0). Protein 
impurities devoid of histidine tails were removed from the agarose 
resin with 75 ml of 50 mM imidazole in buffer B. The polypeptides 
/iPrP(23-231), /*PrP(81-231), and /iPrP(90-231) were eluted with buff-
er E (10 mM Tris, 100 mM Na2P04 , 500 mM imidazole, pH 5.8), 
while the fragment /iPrP(121-231) was eluted with buffer B containing 
150 mM imidazole. After washing the resin with 30 ml of buffer G, 
oxidative refolding and imidazole elution were repeated to obtain a 
second batch of soluble prion protein. Histidine tail-fused PrP was 
dialysed against buffer D (10 mM Na2P04 , pH 5.8), and afterwards 
against water. The histidine tail was removed from the prion protein 
using thrombin (Sigma; 0.1 units/ml). The cleaving reaction was car-
ried out at RT for 1 h in buffer C (5 mM Tris-HCl buffer, pH 8.5). 
The protease was removed from the prion protein fragment /?PrP(121-
231) by loading onto a DE 52 column (10 ml resin; Whatman) equil-
ibrated in buffer C, followed by elution with a 200 ml gradient of 
0-200 mM NaCl. The polypeptides /iPrP(23-231), /zPrP(81-231) and 
/;PrP(90-231) were loaded onto a CM 52 resin (Whatman) equil-
ibrated with buffer I (10 mM Na2P04 , pH 6.5), and eluted with a 
200 ml gradient of 0-500 mM NaCl. The cleaved histidine tail was 
removed by dialysis against water was using a Spectrapor-membrane 
(MW 6000-8000). 
Purified protein was analyzed by SDS-polyacrylamide gel electro-
phoresis in the absence of reducing agent (Fig. 2), N-terminal se-
quencing, and electrospray mass spectrometry. Protein concentration 
was determined using the molar extinction coefficients e276 = 16240 
M" 1 cm"1 for /iPrP(121-231), e276=21640 M"
1 cm"1 for /;PrP(90-
231), e276 = 32440 M"
1 cm"1 for /iPrP(81-231), and e276 = 56940 M"
1 
cm"1 for /;PrP(23-231). 
2.3. NMR spectroscopy 
NMR experiments are reported here for the uniformly 15N-labeled 
human prion protein, /iPrP(23-231), and the 15N-labeled C-terminal 
fragment /;PrP(121-231). The protein concentration was 1 mM in a 
solvent of 90% H2O/10% D 2 0 , and 10 mM [d4]-sodium acetate buffer, 
pH 4.5. NMR spectra were recorded on a 750 MHz Bruker DRX 
spectrometer at 20°C. One-dimensional 1H-NMR spectra were ac-
quired with an acquisition time of 0.1 s, and the spectral range was 
10000 Hz. Two-dimensional "N/H-COSY spectra [24] were acquired 
using spectral widths of C0i(15N) = 1700 Hz and co2(
1H)= 10000 Hz, 
*imax = 74 ms, ?2max = 105 ms, and the time domain data size was 
128 X 1024 complex points. Data processing was performed with the 
program PROSA [25], and the spectral analysis was supported with 
the program XEASY [26]. 
2.4. Circular dichroism spectroscopy 
Circular dichroism spectra were recorded on a Jasco J720 spectro-
polarimeter using a thermostatted cuvette (Helma) with 1 mm path-
length. Measurements were carried out at 14°C in 10 mM potassium 
phosphate buffer, pH 7.0, at a final protein concentration of 8 nM. 
2.5. Fluorescence spectroscopy 
Fluorescence spectra were recorded on a SPEX FLUOROLOG 
spectrometer using a 0.4 X 1 cm cuvette. Measurements were carried 
out at 23°C in 10 mM potassium phosphate buffer pH 7.0, and at a 
final protein concentration of 1 uM. The bandwidth of both the ex-
citation and emission slits was 5 nm. 
3. Results and discussion 
3.1. Expression and purification of hPrP and partial 
sequences thereof 
H u m a n prion protein polypeptides were expressed with an 
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Fig. 1. Scheme summarizing the purification procedure of recombi-
nant human prion protein polypeptides using 'high-affinity column 
refolding'. 
402 R Zahn et al.lFEBS Letters 417 (1997) 400-404 
66 — 
45 — 
36 — 
29 — 
24 -
2 0 -
14 
6.5 
Fig. 2. SDS-polyacrylamide gel electrophoresis of purified /?PrP pol-
ypeptides. M = molecular weight standards (in kDa); 1: WrP(121-
231); 2: /;PrP(90-231); 3: M>rP(81-231); 4: WrP(23-231). The cal-
culated molecular weights of the four APrP polypeptides are 13137 
Da, 16194 Da, 17156 Da, and 22876 Da. Electrophoresis was car-
ried out under non-reducing conditions. Thus, the single band in all 
the protein preparations indicates that purified protein does not 
contain intermolecular disulfide bonds. 
N-terminal histidine tail as inclusion bodies in the cytoplasm 
of E. coli. The histidine tail is composed of 17 amino acids 
comprising the sequence MRGSHHHHHHGLVPRGS, and 
contains a thrombin cleavage site between Arg-15 and Gly-
16. Expression was performed with freshly transformed cells, 
as PrP inclusion bodies are toxic for E. coli, leading to loss of 
the plasmid. The amount of inclusion bodies was very similar 
for the various polypeptides, which were all expressed under 
control of a T7 promoter. 
The purification procedure of PrP proteins is summarized in 
Fig. 1. After sonication and centrifugation of the GdmCl 
denatured E. coli cell lysate, the soluble protein fraction was 
added to a nickel-NTA agarose resin, which has a high affin-
ity for polypeptides that contain six consecutive histidine res-
idues at their N- or C-terminus [27]. Proteins not containing a 
histidine tail were removed by washing the resin with GdmCl 
buffer containing reduced glutathione, to prevent the forma-
tion of intermolecular disulfide bonds in the denatured pro-
tein. Refolding and oxidation are the critical steps for obtain-
ing high yields of correctly folded prion protein [14,19,21], 
and renaturation of the protein by simply diluting out the 
denaturant and the reducing agent leads to considerable pro-
tein aggregation and intermolecular disulfide bond formation. 
However, N-terminal immobilization during refolding via a 
100-0% GdmCl/glutathione gradient prevents protein aggre-
gation and favors intramolecular disulfide bond formation. 
Protein impurities with low affinity for nickel-NTA were re-
moved from the resin with 50 mM imidazole, and monomeric 
prion protein was then eluted at an imidazole concentration of 
> 125 mM. Oligomeric and/or unfolded prion protein re-
mained bound to the resin, but could in part be converted 
to soluble protein in a second column refolding step. The N-
terminal histidine tail was removed using thrombin. Interest-
ingly, thrombin does not cleave within the polypeptide chain 
of the prion protein during the incubation time of about 1 h 
that is necessary for the removal of the histidine tail. In the 
final purification step for APrP(l 21-231), thrombin was re-
moved by anion-exchange chromatography. In order to take 
account of the high content of positive charges in the N-ter-
minal 98-residue peptide segment (the isoelectric point of 
/zPrP(121-231) is at pH 5.8, while those of the longer PrP 
polypeptides range from pH 8.0 to 9.4), intact ItPiP and the 
fragments truncated at codons 81 and 90 were subjected to 
cation-exchange chromatography to remove the protease. Us-
ing this procedure, 10-20 mg of prion protein polypeptide was 
obtained per liter of culture (Fig. 2), also in the minimal 
media needed for isotope labeling with 15N and 13C. 
High-affinity column refolding was also successfully applied 
for the production of recombinant bovine and mouse prion 
proteins of various lengths (to be published). 
3.2. Preliminary spectroscopic characterization of hPrP 
The near-UV CD spectra of the four human prion protein 
polypeptides (Fig. 3A) indicate a high content of a-helix sec-
ondary structure and a low amount of (3-sheet structure. 
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Fig. 3. Near-UV circular dichroism (A) and fluorescence (B) of 
/jPrP polypeptides. Circular dichroism spectra were recorded at a 
protein concentration of 8 (xM in 10 mM potassium phosphate buff-
er, pH 7.0, at 14°C. Fluorescence spectra (excitation wavelength 280 
nm) were recorded at a protein concentration of 1 uM in 10 mM 
potassium phosphate buffer, pH 7.0, at 23°C. 
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Fig. 4. One-dimensional 750 MHz 'H-NMR spectra of APrP(121-
231) (A) and /iPrP(23-231) (B) (solvent 90% H2O/10% D20, 10 mM 
[d4]-sodium acetate pH 4.5). Resonance assignments for selected 
well-separated resonance signals are indicated in A (R. Zahn, R. 
Riek, G. Wider and K. Wiithrich, to be published). The signals of 
the indole groups of the seven Trp residues in intact /jPrP are indi-
cated in B. 
There is an increase in random coil content with increasing 
length of the polypeptides, indicating that the N-terminal half 
of APrP does not form extensive regular secondary structures. 
Interestingly, although the polypeptide sequence 23-120 seems 
to have little or no regular secondary structure, it was suffi-
ciently resistant against protease cleavage by thrombin to en-
able use of the aforementioned purification procedure. 
After excitation at 280 nm, the fluorescence spectra of 
M>rP(81-231) and /;PrP(23-231), which comprise 7 and 3 
Trp residues, respectively, show a maximal fluorescence inten-
sity at 359 nm (Fig. 3B), indicating that the indole rings are 
exposed to solvent. The fluorescence maximum of the single 
Trp residue in M>rP(90-231) is slightly blue-shifted to a wave-
length of 356 nm, indicating that although the indole ring of 
Trp-99 is mostly solvent-exposed, it may have some hydro-
phobic interactions. The C-terminal fragment APrP(121-231) 
is devoid of Trp residues, and its overall fluorescence is con-
comitantly low. 
The JH NMR spectra of M>rP(121-231) and APrP(23-231) 
(Fig. 4) show that the protein preparations are homogeneous, 
and the chemical shift dispersion is typical for globular pro-
teins. Thus, the resonance lines near 0 ppm are representative 
for ring current-shifted methyl resonances in well-structured 
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Fig. 5. Two-dimensional ^N/H-COSY spectra of /iPrP(121-231) (A) and /iPrP(23-231) (B). Resonance assignments for selected well-separated 
resonance signals are indicated in A (R. Zahn, R. Riek, G. Wider and K. Wiithrich, to be published). The rectangle in B contains the Trp in-
dole 15NE-1H cross peaks, which are folded in C0i. 
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globular proteins [28]. Near 10 ppm a group of lines (Fig. 4B) 
represent the resonances of indole N H groups of seven Trp 
residues in APrP(23-231), all of which are located within the 
23-120 segment. The small chemical shift dispersion of these 
lines suggests that the indole rings are solvent-exposed, which 
is in agreement with the C D and fluorescence measurements 
and has also been observed for w P r P [20]. The absence of Trp 
residues in /zPrP(121-231) is confirmed in the 1 H N M R spec-
t rum (Fig. 4A). Similar patterns of the signals near 10 ppm, 
between 5.0 and 6.5 ppm, and near 0 p p m (Fig. 4A,B) indicate 
that the globular structure of the C-terminal fragment is con-
served in the intact protein. The similar structure of the par-
tial sequence 121-231 within the two polypeptides is clearly 
apparent in the two-dimensional 1 5 N, 1 H-COSY N M R spectra 
(Fig. 5). In the spectrum of/iPrP(121-231) (Fig. 5A) we iden-
tified 103 out of 108 expected backbone amide resonances (the 
thrombin cleavage site of the APrP constructs introduces an 
additional Gly-Ser dipeptide preceding the N-terminus of the 
prion protein sequence, so that for /zPrP(121-231) the reso-
nances of Ser and Val-121 are also observed in the ^ N ^ H -
COSY spectrum). All eight expected Gly backbone amide 
protons (Fig. 5A), all eight expected side chain guanidino 
i H N e resonances, and 23 out of 28 expected side chain amide 
resonances have been identified. In the intact protein, cross 
peaks in identical positions to all outstanding chemical shifts 
assigned in the C-terminal domain are observed (Fig. 5). The 
additional cross peaks in the spectrum of APrP(23-231) show 
little XH chemical shift dispersion, as would be expected for an 
extended, 'unfolded' polypeptide [28]. There was no change in 
1 5 N and J H N chemical shifts when the APrP polypeptides de-
scribed here were incubated for several weeks at room temper-
ature, indicating that the purified protein is free of contami-
nating proteases, and thus suitable for structure determination 
by N M R . 
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